Skip to main content

Table 1 Results from clinical trials conducted in advanced, metastatic, radioiodine-refractory and anaplastic thyroid cancers conducted between 2013 and 2017 in the United States (Source: https://clinicaltrials.gov/)

From: Therapeutic advances in anaplastic thyroid cancer: a current perspective

No. Drug Phase Cancer Number of patients Response Rate Progression free survival Overall survival Reference
1 Sorafenib (Bay43–9006, Nexavar) II ATC 20 PR in 2/20 (10%); Stable disease in 5/20 (25%) 1.9 months [107]
2 Carbozantinib III MTC 330 28% 11.2 [108]
3 Efatutazone+ Paclitaxel I ATC 15 PR = 1; SD = 7 3.3 months [39]
4 Pazopanib II Advanced and progressive medullary 35 5/35 9.4 19.9 [109]
5 Fosbretabulin + Paclitaxel/Carboplatin II ATC 8 20% 3.3 5.2 months [110]
6 Vemurafenib   BRAFV600E positive, metastatic, radio-iodine refractory PTC 26 10/26 [110]
7 Axitinib II Advanced thyroid cancer 52 35% 16.1 23.2 [111]
8 Levatinib III Iodine refractor TC 261 64.8% 18.3 [112]
9 Sunitinib (second line of therapy) II Progressive, radio-iodine Refractory thyroid cancer 25 5/20 (25%) 6 months 13 months [113]
10 Cabozantinib (XL-184) III Advanced MTC    11.2 months [114]
11 Dabrafenib plus trametinib II BRAF V600E–mutated anaplastic thyroid cancer 16 69% [23]